Epicardial fat · fat around the heart
Fat Around the Heart: How Epicardial Fat Injures From the Outside In
Epicardial fat is the layer of fat that sits directly on the heart, under its outer sac, touching the heart muscle and the coronary arteries with nothing in between. Healthy, it protects the heart. Inflamed, it can feed plaque, scarring and atrial fibrillation from the outside in. It is seen on an echocardiogram, CT or MRI; Measura does not image it, but it measures the fat and the signals that travel with it.
Most fat sits somewhere that matters only in bulk. This fat sits on the one organ that never gets a day off, wrapped around the very arteries that feed it. Where fat lives turns out to matter as much as how much of it there is.
Why does fat on the heart behave differently from belly fat?
Because it is a different tissue with a different address. A 2022 review in Nature Reviews Cardiology describes epicardial fat as unique in its anatomy and its unobstructed closeness to the heart, with a pattern of active genes and secreted molecules very different from other fat stores. In health it can protect the heart muscle next to it, burning energy in a way that resembles brown fat. In disease it does the opposite, sending inflammatory and scar-promoting signals straight into the tissue beside it.
Belly fat has to send its signals through the bloodstream, diluted along the way. Epicardial fat delivers them by hand.
How can fat outside an artery damage the inside?
The classic picture of heart disease is inside-out: cholesterol-carrying particles and inflammatory cells in the blood work their way into the artery wall. The 2026 Obesity Medicine Association statement on obesity and cardiovascular disease names the other direction, dysfunctional epicardial fat injuring the heart directly, as part of what it calls “sick fat disease”.
The evidence for outside-in injury is tissue you can hold. In 42 patients having bypass surgery, surgeons took paired samples of fat from the surface of the heart and from under the skin. The heart’s fat made significantly more of four inflammatory messengers, interleukin-1 beta, interleukin-6, MCP-1 and TNF-alpha, and was infiltrated with inflammatory cells. That held regardless of diabetes, BMI, or whether the patient took a statin or a blood-pressure drug of the ACE inhibitor or ARB class.
Read that last sentence twice. The standard medicines did not quiet the fat. And the authors noted that blood tests for inflammation may not reflect what is happening in that tissue. A normal high-sensitivity CRP is reassuring, but it does not prove the fat on your heart is calm.
Is fat around the heart linked to atrial fibrillation and heart failure?
Yes. The same review ties fat around the coronary arteries to coronary artery disease and fat over the left atrium to atrial fibrillation, and describes epicardial fat as contributing to the development and worsening of heart failure. An international position statement places epicardial and liver fat alongside visceral fat as emerging cardiometabolic risk factors.
Rhythm is where the nervous system and the heart’s tissue meet. Dr. Padda learned how quickly that meeting can go wrong on himself: during a sauna heat experiment, wearing an EKG, he triggered an irregular rhythm called bigeminy and reversed it with a cold plunge. He took that risk in his own body before talking to anyone else about heat and cold. The lesson he took from it is the one that applies here. The heart’s rhythm responds to its surroundings, and fat that inflames those surroundings is not a passive passenger.
Can you shrink fat around the heart?
Epicardial fat is modifiable. The 2022 review calls it a reliable potential treatment target for medicines with cardiovascular benefit, naming GLP-1 receptor agonists and SGLT2 inhibitors. The outcome trials in obesity-related heart failure line up with that. In STEP-HFpEF, semaglutide produced a mean weight loss of 13.3% against 2.6% on placebo, larger gains in symptoms and walking distance, and a 43.5% drop in CRP. In SUMMIT, among 731 adults with heart failure and obesity, worsening heart failure or cardiovascular death occurred in 9.9% on tirzepatide and 15.3% on placebo over a median of two years. GLP-1 based medicines may be part of your solution, chosen for specific problems after a full evaluation.
The non-drug route works on the same target. Visceral and ectopic fat, the depots that sit in and around organs, respond to diet and exercise, and an international working group found that clinically meaningful drops in waist size come from routine moderate exercise, dietary change or both. The levers are the familiar ones done consistently: cut the acellular carbohydrates that keep insulin high, drop the industrial seed oils, eat enough protein, lift something heavy two or three times a week, and protect sleep. High insulin tells every fat depot to hold on; lowering it lets stored fat be released and burned.
If Measura doesn’t image the heart, what does it measure?
Plainly: Measura does not see epicardial fat. Echocardiography, CT and MRI do, and if your results point that way, your report says so and your physician orders it. What Measura measures are the neighbors that travel with it:
- Trunk and visceral fat estimates from bioimpedance body composition. Visceral and ectopic fat tend to accumulate in the same metabolic setting; how to read the numbers is in how to measure visceral fat.
- Rhythm control from heart rate variability and cardiac autonomic reflex tests, the nerves that steer heart rate and are disturbed in metabolic disease.
- Artery condition from arterial stiffness and endothelial function testing.
- The chemistry of sick fat, fasting insulin, LP-IR, GGT and hs-CRP among them, from laboratory panels.
These are indirect. They do not put a number on the fat over your coronary arteries. They tell you whether you live in the kind of metabolic terrain where that fat turns harmful, and they show whether the terrain is changing as you treat it. For the full two-pathway picture, see fat mass versus sick fat.
If you have chest pain, pressure, sudden shortness of breath, a racing irregular heartbeat with lightheadedness, or new weakness on one side, call 911. Measura testing is for planning, not emergencies.
Frequently asked questions
Does a normal CRP mean the fat around my heart is quiet?
No. In the bypass-surgery study, the fat on the heart was inflamed regardless of blood markers, and the authors cautioned that blood tests may not reflect local tissue inflammation. A normal hs-CRP is one good sign, not a clearance.
Can someone who is not overweight have too much fat around the heart?
Weight is a poor guide to where fat sits. Fat stored around and in the organs can build up in people whose BMI looks normal, which is why trunk fat, waist and insulin are worth measuring even when the scale is reassuring.
Measure the fat you can measure
Trunk fat, insulin, inflammation and heart rhythm control travel with the fat on your heart. Start with those numbers.
4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.
References
- Iacobellis, G. (2022). Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology, 19(9), 593-606. https://doi.org/10.1038/s41569-022-00679-9 (PMID 35296869)
- Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., et al. (2026). Obesity and Cardiovascular Disease: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2026. Obesity Pillars, 20, 100283. https://doi.org/10.1016/j.obpill.2026.100283 (PMID 42729919)
- Mazurek, T., Zhang, L., Zalewski, A., Mannion, J. D., Diehl, J. T., Arafat, H., et al. (2003). Human epicardial adipose tissue is a source of inflammatory mediators. Circulation, 108(20), 2460-2466. https://doi.org/10.1161/01.CIR.0000099542.57313.C5 (PMID 14581396)
- Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., et al. (2019). Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology, 7(9), 715-725. https://doi.org/10.1016/S2213-8587(19)30084-1 (PMID 31301983)
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., et al. (2023). Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 389(12), 1069-1084. https://doi.org/10.1056/NEJMoa2306963 (PMID 37622681)
- Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., et al. (2025). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine, 392(5), 427-437. https://doi.org/10.1056/NEJMoa2410027 (PMID 39555826)
- Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., et al. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177-189. https://doi.org/10.1038/s41574-019-0310-7 (PMID 32020062)
Related reading
- Obesity and Heart Disease: The Weight of Fat and the Sickness of Fat
- Visceral Fat vs Subcutaneous Fat: What Testing Can Show
- Heart Rate Variability
Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed .